{"id":97703,"date":"2025-09-08T08:36:35","date_gmt":"2025-09-08T06:36:35","guid":{"rendered":"https:\/\/www.formycon.com\/?page_id=97703"},"modified":"2026-03-20T10:05:01","modified_gmt":"2026-03-20T09:05:01","slug":"fyb203-aflibercept","status":"publish","type":"page","link":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/","title":{"rendered":"FYB203 Aflibercept"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; equal_height=&#8221;yes&#8221; gutter_size=&#8221;0&#8243; shift_y=&#8221;0&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_use_pixel=&#8221;yes&#8221; position_vertical=&#8221;middle&#8221; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;2&#8243; align_mobile=&#8221;align_center_mobile&#8221; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; column_width_pixel=&#8221;800&#8243;][vc_custom_heading text_color=&#8221;color-155072&#8243; heading_semantic=&#8221;h1&#8243; text_size=&#8221;h5&#8243; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; uncode_shortcode_id=&#8221;251830&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB203[\/vc_custom_heading][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;620649&#8243; text_color_type=&#8221;uncode-palette&#8221;]Aflibercept Biosimilar[\/vc_custom_heading][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;h3&#8243; text_weight=&#8221;300&#8243; text_height=&#8221;fontheight-357766&#8243; uncode_shortcode_id=&#8221;182628&#8243;]FYB203 is approved in the U.S. and Europe for the treatment of severe retinal diseases such as neovascular (wet) age-related macular degeneration. Market launch in the U.S. is expected in the fourth quarter of 2026.[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;585328&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97778&#8243; media_width_use_pixel=&#8221;yes&#8221; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;907757&#8243; media_width_pixel=&#8221;1400&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;513525&#8243;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;134115&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_single_image media=&#8221;97778&#8243; media_lightbox=&#8221;yes&#8221; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;139087&#8243;][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;581096&#8243; back_color_type=&#8221;uncode-palette&#8221; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;842444&#8243;]<strong>Indication Area<br \/>\n<\/strong>Ophthalmology[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;160371&#8243;]<strong>Active Ingredient Group<br \/>\n<\/strong>VEGF Inhibitor[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;467556&#8243;]<strong>Indications of the Reference Drug<br \/>\n<\/strong>Neovascular (\u201cwet\u201d) age-related macular degeneration (nAMD),\u00a0 Diabetic macular edema (DME), Choroidal neovascularization (CNV), Proliferative diabetic retinopathy (PDR), Macular edema following retinal vein occlusion (RVO)*[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;191660&#8243;]<strong>Markt Launch<br \/>\n<\/strong>in Europe in May 2026 and in the U.S. in Q4\/2026; in other regions after loss of exclusivity of the reference drug[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;416285&#8243;]<strong>Aflibercept Market<\/strong><br \/>\nAflibercept and ranibizumab together account for more than 90% of the global market for anti-VEGF therapies. In 2024, the reference drug Eylea\u00ae in dosages of 2mg and 8mg (high dose) together generated sales of around US$9.5 billion.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;205982&#8243; el_width=&#8221;100%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;688852&#8243;]<b>Commercialization partners:<\/b>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; uncode_shortcode_id=&#8221;104467&#8243; limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;189790&#8243; css=&#8221;.vc_custom_1744715179522{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;109078&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97807 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Teva_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Ahzantive\u00ae<br \/>\n<strong>Region:<\/strong> Major Parts of Europa[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;734702&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97795 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Horus_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Baiama\u00ae<br \/>\n<strong>Region:<\/strong> Selected European Countries[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;141585&#8243; css=&#8221;.vc_custom_1744715188716{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;143513&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97809 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Valorum_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Ahzantive\u00ae<br \/>\n<strong>Region:<\/strong> US, Canada[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;239503&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97803 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/NTC_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Baiama\u00ae<br \/>\n<strong>Region:<\/strong> Italy[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;208704&#8243; css=&#8221;.vc_custom_1744715197222{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;191113&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97801 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/MSPharma_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> Fovlya\u00ae<br \/>\n<strong>Region:<\/strong> MENA[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;205526&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97799 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Megalabs_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> N.N.<br \/>\n<strong>Region:<\/strong> Latin America[\/vc_column_text][\/vc_column_inner][vc_column_inner column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/4&#8243; uncode_shortcode_id=&#8221;200910&#8243; css=&#8221;.vc_custom_1744715204142{padding-right: 10px !important;padding-left: 10px !important;}&#8221;][vc_column_text uncode_shortcode_id=&#8221;549329&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97797 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Lotus_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> N.N.<br \/>\n<strong>Region:<\/strong> APAC[\/vc_column_text][vc_separator sep_color=&#8221;color-jevc&#8221; type=&#8221;dotted&#8221; uncode_shortcode_id=&#8221;105679&#8243; el_width=&#8221;60%&#8221; sep_color_type=&#8221;uncode-palette&#8221;][vc_column_text uncode_shortcode_id=&#8221;132558&#8243;]<strong><img decoding=\"async\" class=\"alignnone wp-image-97787 size-full\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/09\/Actor_Logo_180x40.png\" alt=\"\" width=\"180\" height=\"40\" \/><br \/>\n<\/strong><strong>Brand:<\/strong> N.N.<br \/>\n<strong>Region:<\/strong> Australia[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183068&#8243;][vc_separator sep_color=&#8221;&#8221; uncode_shortcode_id=&#8221;149492&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;164809&#8243;]<\/p>\n<div style=\"text-align: right;\">* The specific indication groups approved are listed in the product information<br \/>\nprovided by the EMA or FDA.<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;118803&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97726&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;393355&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;25&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; mobile_visibility=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;202553&#8243; row_height_pixel=&#8221;200&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_empty_space empty_h=&#8221;4&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;157939&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB203 Biosimilar Development[\/vc_custom_heading][vc_empty_space empty_h=&#8221;4&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;0&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;447782&#8243;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;350506&#8243;][vc_single_image media=&#8221;97726&#8243; media_width_percent=&#8221;100&#8243; alignment=&#8221;center&#8221; uncode_shortcode_id=&#8221;213123&#8243;][\/vc_column][\/vc_row][vc_row unlock_row_content=&#8221;yes&#8221; row_height_percent=&#8221;100&#8243; back_color=&#8221;color-200069&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; desktop_visibility=&#8221;yes&#8221; medium_visibility=&#8221;yes&#8221; auto_height_device=&#8221;yes&#8221; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;801105&#8243; back_color_type=&#8221;uncode-palette&#8221;][vc_column column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;879127&#8243;][vc_custom_heading text_color=&#8221;color-186842&#8243; heading_semantic=&#8221;p&#8221; text_size=&#8221;h4&#8243; text_weight=&#8221;700&#8243; uncode_shortcode_id=&#8221;159417&#8243; text_color_type=&#8221;uncode-palette&#8221;]FYB203 Biosimilar Development[\/vc_custom_heading][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;185374&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;102763&#8243; column_width_pixel=&#8221;800&#8243;][vc_row_inner][vc_column_inner width=&#8221;1\/1&#8243;][\/vc_column_inner][\/vc_row_inner][vc_empty_space empty_h=&#8221;3&#8243; mobile_visibility=&#8221;yes&#8221;][vc_accordion typography=&#8221;yes&#8221; gutter_simple=&#8221;0&#8243; uncode_shortcode_id=&#8221;605931&#8243; el_id=&#8221;devdetails&#8221; el_class=&#8221;devdetails&#8221; active_tab=&#8221;0&#8243;][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;FYB203 (Aflibercept) Mode of Action&#8221; tab_id=&#8221;1730916296154-2-101744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;183589&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; subheading=&#8221;Aflibercept is a human recombinant fusion protein that binds to both vascular endothelial growth factor (VEGF-A) and placental growth factor (PLGF). Aflibercept thus suppresses the formation of blood vessels in the retina that impair vision. Like Ranibizumab, Aflibercept is injected directly into the vitreous body of the eye.<\/p>\n<p>Due to their different modes of action, aflibercept and ranibizumab complement each other very well in practice. Some patients show a better response to aflibercept, while others are more responsive to ranibizumab. Our biosimilars are designed to improve access to high-quality and more cost-effective treatment options for ophthalmic surgeons and patients.&#8221; uncode_shortcode_id=&#8221;450226&#8243; heading_custom_size=&#8221;24px&#8221; text_color_type=&#8221;uncode-palette&#8221; text_color_solid=&#8221;#ff0000&#8243;]How does FYB203 (Aflibercept) work?[\/vc_custom_heading][vc_column_text text_lead=&#8221;yes&#8221; uncode_shortcode_id=&#8221;193369&#8243;]<\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ahzantive-epar-medicine-overview_en.pdf\" target=\"_blank\" rel=\"noopener\">Further Information<\/a><\/p>\n<p>[\/vc_column_text][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Development and Commercialization Milestones&#8221; tab_id=&#8221;1730790947-1-351744699040478&#8243;][vc_row_inner limit_content=&#8221;&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;188630&#8243;][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;127853&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">March 2026<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\"><br \/>\n<span style=\"color: #000000;\"><span style=\"font-size: 21.3333px;\">Settlement agreement with Regeneron and Bayer secures EU license date in May 2026<\/span><\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-secures-license-date-for-aflibercept-2-mg-biosimilar-fyb203-in-europe-and-further-territories-following-settlement-with-regeneron-and-bayer\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;691940&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">NTC becomes commercialization partner for FYB203\/Baiama<strong><sup>\u00ae<\/sup><\/strong> in Italy<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ntc-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-baiama-in-italy\/ \" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;161123&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Commercialization partnerships for Australia and Latin America with Actor and Megalabs<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/?post_type=press_release&amp;p=98845\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;431012&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">October 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Settlement agreement with Regeneron secures U.S. license date in Q4\/2026<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-secures-u-s-license-date-for-proposed-aflibercept-biosimilar-fyb203-following-settlement-and-license-agreement-with-regeneron\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;169092&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">September 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Horus Pharma becomes additional commercialization partner in selected European countries<br \/>\n<\/span><a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/horus-pharma-becomes-additional-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-in-selected-european-countries-under-the-brand-name-baiama\/\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;155297&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">US biosimilar specialist Valorum Biologics becomes commercialzation partner for the U.S. and Canada<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/u-s-biosimilar-specialist-valorum-biologics-llc-becomes-commercialization-partner-for-formycons-eylea-biosimilar-fyb203-ahzantive-aflibercept-mrbb-in-the-united-states-and-cana\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;171015&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Approval of FYB203 in the UK<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-receives-regulatory-approval-in-the-uk-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-name-ahzantive\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;969560&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Lotus Pharmaceutical becomes commercialization partner for the APAC region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/lotus-pharmaceutical-becomes-strategic-partner-for-the-commercialization-of-formycons-eylea-biosimilar-fyb203-ahzantive-in-the-asia-pacific-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;109958&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB203 approved by the European Commission<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-receives-eu-approval-for-fyb203-aflibercept-a-biosimilar-to-eylea-under-the-brand-names-ahzantive-and-baiama\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;203763&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">January 2025<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Teva becomes commercialization partner for FYB203 in major parts of Europe and Israel<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/teva-becomes-strategic-commercialization-partner-for-formycons-biosimilar-candidate-fyb203-eylea-aflibercept-in-major-parts-of-europe-and-israel\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;150370&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB203 receives positive CHMP opinion for the EU marketing authorization\u00a0<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate-to-eylea-under-the-tradenames-ahzantive-and-baiama\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;209204&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">July 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">U.S. approval by the FDA<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-receives-fda-approval-for-fyb203-ahzantive\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;939084&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2024<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">MS Pharma becomes commercialization partner for the MENA region<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ms-pharma-becomes-partner-for-the-commercialization-of-fyb203-formycons-biosimilar-candidate-to-eylea-aflibercept-in-the-mena-region\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;799337&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">December 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">EMA acceptance of the MAA for FYB203<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/maa-acceptance-fyb203\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;598877&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">November 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">EMA submission for FYB203<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/ema-submission-fyb203\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;764571&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">File Acceptance for FYB203 by the U.S. Food and Drug Administration (FDA)<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/file-acceptance-fyb203\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;154053&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">June 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Submission of the biologics license application for FYB203 to the FDA<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/fda-submission-for-fyb203\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;455856&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2023<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">FYB203 shows comparable efficacy to the reference product Eylea\u00ae\u00a0in Phase III Study<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycons-aflibercept-biosimilar-kandidat-fyb203-zeigt-in-phase-iii-studie-vergleichbare-wirksamkeit-zum-referenzprodukt-eylea1\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;143649&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">August 2020<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Start of the clinical development<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-and-bioeq-enroll-first-patient-in-phase-iii-study-with-aflibercept-biosimilar-fyb203\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;144871&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">February 2016<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Formycon discloses details regarding the biosimilar candidate FYB203<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-discloses-details-on-second-pipeline-product-fyb203-is-a-biosimilar-for-eylea-aflibercept\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][vc_message message_color=&#8221;color-200069&#8243; css_animation=&#8221;top-t-bottom&#8221; uncode_shortcode_id=&#8221;643915&#8243; message_color_type=&#8221;uncode-palette&#8221;]<span style=\"color: #000000;\">May 2015<\/span><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-full wp-image-96083\" src=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2025\/04\/YellowLine_65px.png\" alt=\"\" width=\"65\" height=\"2\" \/><br \/>\n<span style=\"font-size: 16pt; color: #000000;\">Out-licensing of FYB203 to Santo Holding GmbH<\/span><br \/>\n<a href=\"https:\/\/www.formycon.com\/en\/blog\/press-release\/formycon-ag-signs-licensing-agreement-for-its-fyb203-biosimilar\/\" target=\"_blank\" rel=\"noopener\">[Further Information]<\/a>[\/vc_message][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][vc_accordion_tab gutter_size=&#8221;2&#8243; column_padding=&#8221;2&#8243; title=&#8221;Scientific Publications on FYB203&#8243; tab_id=&#8221;1767784877688-2-10&#8243;][vc_row_inner][vc_column_inner column_width_percent=&#8221;100&#8243; align_horizontal=&#8221;align_center&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;573995&#8243;][vc_custom_heading heading_semantic=&#8221;p&#8221; text_size=&#8221;custom&#8221; text_weight=&#8221;700&#8243; text_transform=&#8221;uppercase&#8221; text_height=&#8221;fontheight-179065&#8243; text_space=&#8221;fontspace-210350&#8243; separator_color=&#8221;yes&#8221; separator=&#8221;yes&#8221; sub_lead=&#8221;yes&#8221; sub_reduced=&#8221;yes&#8221; uncode_shortcode_id=&#8221;142537&#8243; heading_custom_size=&#8221;24px&#8221;]Clinical data from the Phase III efficacy study[\/vc_custom_heading][vc_empty_space empty_h=&#8221;2&#8243;][vc_gallery el_id=&#8221;gallery-130684&#8243; type=&#8221;carousel&#8221; medias=&#8221;99096,97767,97765&#8243; carousel_lg=&#8221;3&#8243; carousel_md=&#8221;2&#8243; carousel_sm=&#8221;1&#8243; gutter_size=&#8221;3&#8243; media_items=&#8221;media|custom_link|original,description,icon,caption&#8221; carousel_interval=&#8221;3000&#8243; carousel_navspeed=&#8221;400&#8243; carousel_loop=&#8221;yes&#8221; stage_padding=&#8221;0&#8243; single_overlay_opacity=&#8221;50&#8243; single_padding=&#8221;2&#8243; uncode_shortcode_id=&#8221;173220&#8243; single_link=&#8221;url:https%3A%2F%2Fwww.formycon.com%2Funternehmen%2Fkontakt%2F|title:Kontakt&#8221; items=&#8221;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&#8221;][vc_empty_space empty_h=&#8221;2&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;762269&#8243; row_height_pixel=&#8221;600&#8243;][vc_column column_width_use_pixel=&#8221;yes&#8221; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;-3&#8243; shift_y_fixed=&#8221;yes&#8221; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;372897&#8243; column_width_pixel=&#8221;1200&#8243;][vc_row_inner row_inner_height_percent=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; limit_content=&#8221;&#8221; uncode_shortcode_id=&#8221;149764&#8243; css=&#8221;.vc_custom_1757693219486{padding-right: 112px !important;}&#8221;][vc_column_inner column_width_percent=&#8221;100&#8243; position_vertical=&#8221;bottom&#8221; gutter_size=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; shift_x=&#8221;0&#8243; shift_y=&#8221;0&#8243; shift_y_down=&#8221;0&#8243; z_index=&#8221;0&#8243; medium_width=&#8221;0&#8243; mobile_width=&#8221;0&#8243; width=&#8221;1\/1&#8243; uncode_shortcode_id=&#8221;745787&#8243;][vc_empty_space empty_h=&#8221;3&#8243;][vc_column_text text_lead=&#8221;small&#8221; uncode_shortcode_id=&#8221;361331&#8243;]<\/p>\n<div style=\"text-align: right;\">Eylea\u00ae is a registered trademark of Regeneron Pharmaceuticals Inc.<br \/>\nAhzantive\u00ae is a registered trademark of Klinge Biopharma GmbH<\/div>\n<div style=\"text-align: right;\">Baiama\u00ae is a registered trademark of Klinge Biopharma GmbH<\/div>\n<div style=\"text-align: right;\">Fovlya\u00ae is a registered trademark of MS Pharma<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]<\/p>\n","protected":false},"author":23,"featured_media":81308,"parent":78082,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-97703","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FYB203 Aflibercept - Formycon AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FYB203 Aflibercept - Formycon AG\" \/>\n<meta property=\"og:description\" content=\"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/\" \/>\n<meta property=\"og:site_name\" content=\"Formycon AG\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T09:05:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/\",\"url\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/\",\"name\":\"FYB203 Aflibercept - Formycon AG\",\"isPartOf\":{\"@id\":\"https:\/\/www.formycon.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg\",\"datePublished\":\"2025-09-08T06:36:35+00:00\",\"dateModified\":\"2026-03-20T09:05:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage\",\"url\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg\",\"contentUrl\":\"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg\",\"width\":1600,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.formycon.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilars\",\"item\":\"https:\/\/www.formycon.com\/en\/biosimilars\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FYB203 Aflibercept\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.formycon.com\/en\/#website\",\"url\":\"https:\/\/www.formycon.com\/en\/\",\"name\":\"Formycon AG\",\"description\":\"Global Quality Biosimilars\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.formycon.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FYB203 Aflibercept - Formycon AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/","og_locale":"en_US","og_type":"article","og_title":"FYB203 Aflibercept - Formycon AG","og_description":"[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;0&#8243; bottom_padding=&#8221;0&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243; content_parallax=&#8221;0&#8243; uncode_shortcode_id=&#8221;209039&#8243; row_name=&#8221;bla&#8221;][vc_column column_width_percent=&#8221;100&#8243; gutter_size=&#8221;3&#8243; override_padding=&#8221;yes&#8221; column_padding=&#8221;3&#8243; back_color=&#8221;color-xsdn&#8221; overlay_alpha=&#8221;50&#8243; [&hellip;]","og_url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/","og_site_name":"Formycon AG","article_modified_time":"2026-03-20T09:05:01+00:00","og_image":[{"width":1600,"height":800,"url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/","url":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/","name":"FYB203 Aflibercept - Formycon AG","isPartOf":{"@id":"https:\/\/www.formycon.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage"},"image":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage"},"thumbnailUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg","datePublished":"2025-09-08T06:36:35+00:00","dateModified":"2026-03-20T09:05:01+00:00","breadcrumb":{"@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/"]}]},{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#primaryimage","url":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg","contentUrl":"https:\/\/www.formycon.com\/wp-content\/uploads\/2018\/09\/fyb203-formycon-keyvisual.jpg","width":1600,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/www.formycon.com\/en\/biosimilars\/fyb203-aflibercept\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.formycon.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilars","item":"https:\/\/www.formycon.com\/en\/biosimilars\/"},{"@type":"ListItem","position":3,"name":"FYB203 Aflibercept"}]},{"@type":"WebSite","@id":"https:\/\/www.formycon.com\/en\/#website","url":"https:\/\/www.formycon.com\/en\/","name":"Formycon AG","description":"Global Quality Biosimilars","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.formycon.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-26 14:52:32","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"translation_priority","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/comments?post=97703"}],"version-history":[{"count":6,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97703\/revisions"}],"predecessor-version":[{"id":99361,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/97703\/revisions\/99361"}],"up":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/pages\/78082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media\/81308"}],"wp:attachment":[{"href":"https:\/\/www.formycon.com\/en\/wp-json\/wp\/v2\/media?parent=97703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}